RSS   Newsletter   Contact   Advertise with us
Post Online Media

Director Richard Heyman to retire from Organovo Holdings

Richard HeymanOrganovo Holdings, a biotechnology company, announced that Richard Heyman wants to retire from his position as a member of the board at the AGM scheduled to be held on August 17, 2016.
Article continues below

READ MORE Organovo nominated Richard A. Heyman to board of directors

Dr. Heyman has been nominated to be elected to the board of directors at the annual meeting on August 21, 2013. He is an experienced life science executive who was elected as chief executive officer of Aragon Pharmaceuticals, which he co-founded in 2009.

Previously, he was Chief Scientific Officer at Kalypsys.

In 1999, Dr. Heyman co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases. X-Ceptor was acquired by Exelixis in 2004.

Before X-Ceptor, Dr. Heyman was Vice President of Research at Ligand Pharmaceuticals. He was an NIH postdoctoral fellow and staff scientist at the Salk Institute for Biological Studies.

Dr. Heyman received a PhD in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy